(Q41758836)

8 October 2017

title

High-dose chemotherapy (CTM) for breast cancer (English)

1 reference

8 October 2017

3

Rugo HS

1 reference

8 October 2017

Damon LE

1

1 reference

8 October 2017

Wolf JL

2

1 reference

8 October 2017

Gold E

4

1 reference

8 October 2017

Zander AR

5

1 reference

8 October 2017

Cassidy M

6

1 reference

8 October 2017

Cecchi G

7

1 reference

8 October 2017

Cohen N

8

1 reference

8 October 2017

Irwin D

9

1 reference

8 October 2017

Tracy M

10

1 reference

8 October 2017

Ries CA

11

1 reference

8 October 2017

Linker CA

12

1 reference

8 October 2017

language of work or name

English

0 references

publication date

1 August 2000

1 reference

Bone Marrow Transplantation

8 October 2017

published in

1 reference

8 October 2017

volume

26

1 reference

8 October 2017

issue

3

1 reference

8 October 2017

page(s)

257-268

1 reference

Bone marrow autotransplantation for solid tumors--prospects

8 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702481

7 January 2021

Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702481

7 January 2021

The importance of dose intensity in chemotherapy of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702481

7 January 2021

High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702481

7 January 2021

Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702481

7 January 2021

High-dose chemotherapy with autologous bone marrow transplantation for the treatment of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702481

7 January 2021

Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702481

7 January 2021

High-dose chemotherapy for breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702481

7 January 2021

High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702481

7 January 2021

High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702481

7 January 2021

Pulmonary drug toxicity in patients with primary breast cancer treated with high-dose combination chemotherapy and autologous bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702481

7 January 2021

Acute lung injury following treatment with high-dose cyclophosphamide, cisplatin, and carmustine: pharmacodynamic evaluation of carmustine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702481

7 January 2021

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702481

7 January 2021

A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702481

7 January 2021

Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702481

7 January 2021

Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702481

7 January 2021

Diffuse alveolar hemorrhage in autologous bone marrow transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702481

7 January 2021

Corticosteroid therapy for diffuse alveolar hemorrhage in autologous bone marrow transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702481

7 January 2021

Comparison of different trials of adjuvant chemotherapy in stage II breast cancer using a natural history data base

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702481

7 January 2021

Sixteen-week dose-intense chemotherapy in the adjuvant treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702481

7 January 2021

Adjuvant systemic therapy in women with early-stage breast cancer at high risk for relapse

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702481

7 January 2021

Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702481

7 January 2021

Clinical course of patients with breast cancer with ten or more positive nodes who were treated with doxorubicin-containing adjuvant therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702481

7 January 2021

Combined chemotherapy and radiotherapy for patients with breast cancer and extensive nodal involvement

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702481

7 January 2021

Patient selection in high-dose chemotherapy trials: relevance in high-risk breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702481

7 January 2021

High-dose chemotherapy and stem-cell rescue in the treatment of high-risk breast cancer: prognostic indicators of progression-free and overall survival

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702481

7 January 2021

Outcome of extensive evaluation before adjuvant therapy in women with breast cancer and 10 or more positive axillary lymph nodes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702481

7 January 2021

High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702481

7 January 2021

Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702481

7 January 2021

Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702481

7 January 2021

Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702481

7 January 2021

Inflammatory breast cancer: a review

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702481

7 January 2021

High-dose consolidation therapy with autologous stem cell rescue in stage IV breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702481

7 January 2021

High-dose chemotherapy with reinfusion of purged autologous bone marrow following dose-intense induction as initial therapy for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702481

7 January 2021

Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: a feasibility study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702481

7 January 2021

Treatment of metastatic breast cancer with a split-course high-dose chemotherapy regimen and autologous bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702481

7 January 2021

Rapid administration of multiple cycles of high-dose myelosuppressive chemotherapy in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702481

7 January 2021

Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702481

7 January 2021

Factors predicting long-term survival for metastatic breast cancer patients treated with high-dose chemotherapy and bone marrow support

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702481

7 January 2021

Factors predicting for response, time to treatment failure, and survival in women with metastatic breast cancer treated with DAVTH: a prospective Eastern Cooperative Oncology Group study.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702481

7 January 2021

Dihydroxyanthracenedione: A Promising New Drug in the Treatment of Metastatic Breast Cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702481

7 January 2021

Mitoxantrone: a new anticancer drug with significant clinical activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702481

7 January 2021

A comparison of mitoxantrone and doxorubicin in breast cancer.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702481

7 January 2021

Mitoxantrone in advanced breast cancer--a phase II study with special attention to cardiotoxicity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702481

7 January 2021

A phase II study of mitoxantrone, etoposide, and thiotepa with autologous marrow support for patients with relapsed breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702481

7 January 2021

Intensive chemotherapy with autologous bone marrow transfusion as primary treatment in women with breast cancer and more than five involved axillary lymph nodes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1702481

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1702481

1 reference

Dimensions Publication ID

8 October 2017

1018206060

0 references

1 reference